INVEGA combines: The active metabolite of RISPERDAL® (risperidone) Innovative OROS® extended-release technology INVEGA demonstrated: Significant efficacy in the positive and negative symptoms of schizophrenia, Low weight gain and EPS rates comparable with placebo at the recommended 6-mg dose Total EPS-related adverse events at the 9-mg and 12-mg doses were 25, and 26,, respectively (versus 11, for placebo) The proportion of subjects having a weight gain of 7, body weight were comparable with placebo (5,) for 3 mg (7,) and 6 mg (6,). a higher incidence was seen for 9 mg (9,) and 12 mg (9,) Extensively studied in: 1665 patients with moderate to severe schizophrenia INVEGA,easy convenient dosing: Less than 10, of the dose is metabolized by any of the 4 identified metabolic pathways Not expected to cause clinically important interactions with drugs metabolized by the CYP450 pathway No dose adjustments for patients with mild to moderate hepatic impairment The short-term efficacy of INVEGA (3 to 15 mg once daily) was established in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in non-elderly adult subjects (mean age of 37) who met DSM-IV criteria for schizophrenia: INVEGA delivered a full range of symptom control INVEGA offered an incidence of weight gain similar to that for placebo INVEGA delivered discontinuation rates due to adverse events that are similar to those for placebo across all doses Please see Product Details. Please see the full US Prescribing Information.
In addition to its specific indications for Bipolar I Disorder, ABILIFY is indicated for the treatment of schizophrenia including maintaining stability in adults who had been symptomatically stable on other antipsychotic medications for periods of three months or longer and observed for relapse during a period of up to 26 weeks. Physicians who elect to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual.
Ketamine is a dissociative anesthetic that distorts the user's perception of reality. Ketamine abuse often leads to side effects which require treatment.
RU
Private
$6.6M Revenue
http://www.ketamine.com
Related Companies
No related companies found at this time.
Learn More
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5
free lookups.
Get contact details of over 700M profiles across 60M
companies – all with industry-leading accuracy. Sales and Recruiter users, try out our
Email Finder Extension.
Find business and personal emails and mobile phone numbers
with exclusive coverage across niche job titles, industries, and more
for unparalleled targeting. Also
available via our
Contact Data API.